Journal article
Leukemia inhibitory factor (LIF)
NA Nicola, JJ Babon
Cytokine and Growth Factor Reviews | Published : 2015
Abstract
Leukemia inhibitory factor (LIF) is the most pleiotropic member of the interleukin-6 family of cytokines. It utilises a receptor that consists of the LIF receptor β and gp130 and this receptor complex is also used by ciliary neurotrophic growth factor (CNTF), oncostatin M, cardiotrophin1 (CT1) and cardiotrophin-like cytokine (CLC). Despite common signal transduction mechanisms (JAK/STAT, MAPK and PI3K) LIF can have paradoxically opposite effects in different cell types including stimulating or inhibiting each of cell proliferation, differentiation and survival. While LIF can act on a wide range of cell types, LIF knockout mice have revealed that many of these actions are not apparent during ..
View full abstractGrants
Awarded by State Government of Victoria
Funding Acknowledgements
The authors' original work was supported by grants from the National Health and Medical Research Council, Australia (program grants 461219,1016647; fellowship grants 637300, 1078737 NAN, The Independent Research Institutes Infrastructure Scheme 361646) the Australian Research Council (future fellowship FT110100169 JJB), the National Institutes of Health, Bethesda, Md (Grant RO1CA22556) and Operational Infrastructure Support grants from the State Government of Victoria. Peter Maltezos is thanked for help with preparation of the figures.